Midas Management’s United Therapeutics UTHR Stock Holding History

Midas Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4,025	Closed	-$438K	–	129
2018 Q4	$438K	Hold	4,025	–	–	0.21%	105
2018 Q3	$515K	Hold	4,025	–	–	0.23%	101
2018 Q2	$455K	Hold	4,025	–	–	0.22%	100
2018 Q1	$452K	Hold	4,025	–	–	0.21%	100
2017 Q4	$595K	Hold	4,025	–	–	0.24%	111
2017 Q3	$472K	Hold	4,025	–	–	0.25%	95
2017 Q2	$522K	Hold	4,025	–	–	0.28%	98
2017 Q1	$545K	Hold	4,025	–	–	0.29%	104
2016 Q4	$577K	Buy	4,025 +3,350	+496%	+$428K	0.27%	125
2016 Q3	$80K	Hold	675	–	–	0.05%	139
2016 Q2	$71K	Hold	675	–	–	0.04%	149
2016 Q1	$75K	Buy	+675	New	+$85.4K	0.04%	165

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Midas Management's UTHR Position: Q1 2019 in Review

Midas Management sold out of United Therapeutics (UTHR) in Q1 2019, closing a stake of 4,025 shares — an estimated $438K sold.

Midas Management first reported a position in UTHR in Q1 2016 and held it in 12 quarters. The position peaked at $595K in Q4 2017. 378 funds tracked by Wall St. Rank hold UTHR as of Q1 2019.

Midas Management reported no remaining United Therapeutics position as of Q1 2019 after selling out during the quarter.
Midas Management sold 4,025 United Therapeutics shares in Q1 2019, an estimated $438K.
Midas Management first reported a position in United Therapeutics in Q1 2016 and held it in 12 quarters.
Midas Management's United Therapeutics position peaked at $595K in Q4 2017.
378 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2019.

Based on Midas Management's 13F filing for Q1 2019, filed 25 Apr 2019.